# rs56007086 and Breast cancer (16q12)

Configuration `no_qbic`, named mode, seed 0. Models: generator deepseek/deepseek-v4.1-flash-1017, critic deepseek/deepseek-v4.1-flash-1017, summariser deepseek/deepseek-v4.1-flash-1017. Cost $0.02 over 7 model calls; 188 s.

Variant `chr16:52565398:G>A` (germline); expression context: DepMap:ACH-000019 (MCF7).

## Ranked chains

### 1. H1_null: No TF-mediated effect of rs56007086; linked or elsewhere-functional variant, or no allelic effect (p = 0.58)

Null chain: no TF-mediated effect of this variant.

Predictions: Allele-specific ChIP/CUT&RUN at chr16:52565398 shows no reproducible imbalance for FOXA1, GATA3, or other MCF-7-bound TFs.; The functional variant is the nearby dELS EH38E3180851 or another linked base, not rs56007086 itself.; No breast-tissue eQTL or variant-specific GWAS/literature signal is found for rs56007086 (E15-E17, E19, E20).

Falsified if: A reproducible allele-specific TF occupancy difference is shown at chr16:52565398 in a heterozygous breast cancer line.; CRISPR base editing of rs56007086 alone changes TOX3/CASC16 expression or enhancer activity in breast cells.

### 2. H2_FOXA1: FOXA1 loss on the alt allele reduces TOX3 enhancer activity (p = 0.24)

TF FOXA1 (QBiC-SELEX coverage own_model), ref allele binds more; element ENSR16_9QTBS / nearby dELS EH38E3180851; gene TOX3; cell type MCF-7 breast cancer cells.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | I hypothesize that ref G binds FOXA1 more strongly than alt A. FOXA1 is selected as a candidate because E05 reports MCF-7 ChIP-seq peaks containing the variant and high MCF7 expression (88.38 TPM, rank 28/1626); this is occupancy and expression evidence only. No QBiC-SELEX model or allele-specific binding data for FOXA1 are provided, so the ref>alt direction is unproven. | weak | [E04](#e04), [E05](#e05) |
| element | The variant lies in the VEP-annotated enhancer ENSR16_9QTBS and 38 bp from the ENCODE dELS EH38E3180851. The variant base itself is not inside a called cCRE, and E03 reports maxima across biosamples, so enhancer activity at this exact base in MCF-7 is inferred rather than shown. | weak | [E01](#e01), [E03](#e03) |
| gene | TOX3 is the nearest protein-coding gene, 17.6 kb away, and CASC16 overlaps the variant. TOX3 has a general breast-cancer association (E21), but E18a concerns rs4784227 and E18b is locus-level only; no variant-specific evidence shows that rs56007086 regulates TOX3 or CASC16. | weak | [E01](#e01), [E02](#e02), [E18a](#e18a), [E18b](#e18b), [E21](#e21) |
| cell_type | MCF-7 is the matching breast cancer biosample and has FOXA1 ChIP-seq peaks containing the variant. | supported | [E04](#e04), [E05](#e05) |
| phenotype | This chain predicts that alt A reduces FOXA1-dependent enhancer activity and TOX3 output, contributing to breast cancer risk at 16q12. However, no variant-specific GWAS, eQTL, or literature evidence establishes this direction: E15-E17 and E20 are null, E19 finds no variant-specific literature, and E21 is only a general TOX3-breast-cancer association. | missing | [E15](#e15), [E16](#e16), [E17](#e17), [E19](#e19), [E20](#e20), [E21](#e21) |

Predictions: Allele-specific FOXA1 ChIP/CUT&RUN in a heterozygous breast cancer line shows stronger FOXA1 occupancy on ref G than alt A.; FOXA1 acute degradation or knockdown reduces enhancer activity from the ref allele more than from the alt allele.; If FOXA1 activates this element, TOX3 expression is lower when the alt A allele is present.

Falsified if: No allele-specific FOXA1 occupancy difference is detected at this base in a heterozygous breast cancer line.; FOXA1 perturbation does not change TOX3 or CASC16 expression from this element.; The alt allele shows equal or stronger FOXA1 binding in a clean allele-specific assay.

### 3. H3_GATA3: GATA3 loss on the alt allele alters TOX3 enhancer output (p = 0.18)

TF GATA3 (QBiC-SELEX coverage own_model), ref allele binds more; element ENSR16_9QTBS / nearby dELS EH38E3180851; gene TOX3; cell type MCF-7 breast cancer cells.

| Step | Claim | Status | Evidence |
| --- | --- | --- | --- |
| binding | I hypothesize that ref G binds GATA3 more strongly than alt A. GATA3 is selected as a candidate because E06 reports MCF-7 ChIP-seq peaks containing the variant and very high MCF7 expression (346.04 TPM, rank 5/1626); this is occupancy and expression evidence only. No QBiC-SELEX model or allele-specific binding data for GATA3 are provided, so the ref>alt direction is unproven. | weak | [E04](#e04), [E06](#e06) |
| element | The variant is in the VEP enhancer ENSR16_9QTBS and near the ENCODE dELS EH38E3180851, consistent with a regulatory element. The variant base is not in a called cCRE, and E03 does not establish MCF-7-specific activity at this base. | weak | [E01](#e01), [E03](#e03) |
| gene | TOX3 is the closest protein-coding gene at 17.6 kb and CASC16 overlaps the variant. The literature supports TOX3 as a breast-cancer locus generally (E18a, E18b, E21), but not rs56007086 specifically as the causal base regulating TOX3 or CASC16. | weak | [E01](#e01), [E02](#e02), [E18a](#e18a), [E18b](#e18b), [E21](#e21) |
| cell_type | GATA3 occupancy at this element is reported in MCF-7, the matching breast cancer biosample. | supported | [E04](#e04), [E06](#e06) |
| phenotype | This chain predicts that alt A weakens GATA3 binding and changes TOX3 enhancer activity in breast cells, contributing to breast cancer risk at 16q12. No variant-specific GWAS, eQTL, or literature evidence establishes this direction; E15-E17 and E20 are null, E19 finds no variant-specific literature, and E21 is only a general TOX3 association. | missing | [E15](#e15), [E16](#e16), [E17](#e17), [E19](#e19), [E20](#e20), [E21](#e21) |

Predictions: Allele-specific GATA3 ChIP/CUT&RUN in a heterozygous breast cancer line shows stronger GATA3 occupancy on ref G than alt A.; GATA3 perturbation changes TOX3/CASC16 expression from this enhancer in MCF-7.; The allelic effect is GATA3-dependent and not explained by FOXA1 co-occupancy alone.

Falsified if: GATA3 occupancy over this base is not allele-specific in a heterozygous breast cancer line.; GATA3 knockdown does not affect TOX3 or CASC16 expression from this locus.; The variant disrupts a different TF's motif and GATA3 binding is unchanged.

## Prediction matrix

| Test | Cost | Separates top two | H1_null | H2_FOXA1 | H3_GATA3 |
| --- | --- | --- | --- | --- | --- |
| Reanalyse existing MCF-7 FOXA1 ChIP-seq/CUT&RUN reads for allelic imbalance at rs56007086 | low | yes | No reproducible ref>alt FOXA1 imbalance at the variant base. | Ref G shows greater FOXA1 occupancy than alt A at the variant base. | No FOXA1 allelic imbalance; any GATA3 effect would be separate. |
| Allele-specific GATA3 ChIP/CUT&RUN in a heterozygous breast cancer line at rs56007086 | medium | no | No reproducible GATA3 allelic imbalance at the variant base. | No GATA3 allelic imbalance; FOXA1 is the proposed allele-specific TF. | Ref G shows greater GATA3 occupancy than alt A. |
| CRISPR base edit G>A at rs56007086 in heterozygous breast cancer cells, then measure TOX3/CASC16 expression and enhancer activity | high | yes | No allele-dependent change in TOX3/CASC16 expression or enhancer activity. | Alt A reduces FOXA1-dependent enhancer activity and, if FOXA1 activates the element, lowers TOX3 expression. | Alt A reduces GATA3-dependent enhancer activity and, if GATA3 activates the element, lowers TOX3 expression. |
| Acute FOXA1 degradation/knockdown in MCF-7 with endogenous TOX3/CASC16 readout or allele-specific reporter | medium | yes | No base-specific effect attributable to rs56007086. | FOXA1 loss reduces ref-allele enhancer activity more than alt-allele activity. | No FOXA1-specific effect at this base; GATA3 remains the candidate. |
| Breast mammary tissue eQTL lookup for rs56007086 with TOX3 and CASC16 as targets | low | no | No significant eQTL for rs56007086. | No significant eQTL, or at most a weak alt-A effect on TOX3 if FOXA1 activates the element. | No significant eQTL, or at most a weak alt-A effect on TOX3 if GATA3 activates the element. |

## Next experiment

Reanalyse existing MCF-7 FOXA1 ChIP-seq/CUT&RUN reads (e.g., E05/ENCSR126YEB) for allele-specific read counts over rs56007086 in a heterozygous sample; this is the cheapest test that separates H1_null from H2_FOXA1. If raw reads or heterozygosity are unavailable, perform allele-specific FOXA1 CUT&RUN in a heterozygous breast cancer line at this base.

## Investigate calls

- literature_search({"query": "rs56007086 allele-specific FOXA1 GATA3 SPDEF NR2F2 binding breast cancer"})
- eqtl_lookup({"tissue": "Breast - Mammary Tissue"})
- gene_disease({"gene": "TOX3"})

## Flags

- literature_fallback: no hits for 'rs56007086 AND TOX3 AND "breast cancer"'; dropped the rsID

Citation support: 1.00 of links cite only evidence that passed every check.

## Evidence

<a id="e01"></a>**E01** variant_annotation, Ensembl VEP (GRCh38) (https://rest.ensembl.org/vep/human/region/16:52565398-52565398:1/A?content-type=application/json&Conservation=1; retrieved 2026-10-26T02:25:34+00:00)

> Variant chr16:52565398:G>A (GRCh38), allele string G/A
> Known IDs: rs56007086
> Most severe consequence: intron_variant
> Regulatory features: ENSR16_9QTBS enhancer
> GERP conservation score at the site: -4.73
> Transcript consequences: CASC16 (intron_variant, non_coding_transcript_variant)

<a id="e02"></a>**E02** nearest_genes, Ensembl overlap (protein_coding) (https://rest.ensembl.org/overlap/region/human/16:51565398-53565398?feature=gene;biotype=protein_coding;content-type=application/json; retrieved 2026-10-26T02:25:46+00:00)

> 6 protein-coding genes within 1000 kb of chr16:52565398:G>A, by distance to TSS:
> TOX3: 17.6 kb from TSS (upstream, strand -1)
> CHD9NB: 487.5 kb from TSS (downstream, strand -1)
> CHD9: 489.6 kb from TSS (upstream, strand +1)
> RBL2: 868.6 kb from TSS (upstream, strand +1)
> AKTIP: 939.0 kb from TSS (downstream, strand -1)
> HNRNPA1L3: 1012.0 kb from TSS (downstream, strand +1)

<a id="e03"></a>**E03** ccre_lookup, ENCODE v4 cCRE registry (ENCFF420VPZ) and SCREEN (https://screen-beta-api.wenglab.org/dataws/cre_table; retrieved 2026-10-26T02:25:06+00:00)

> No cCRE overlaps the variant; nearest is EH38E3180851 (dELS) 38 bp away.
> SCREEN: 1 cCREs within 500 bp (max z-score across ENCODE biosamples):
> EH38E3180851 dELS: DNase z 4.2, H3K27ac z 6.1, H3K4me3 z 1.8, CTCF z 1.9; nearby genes CASC16, TOX3, AC026462.5
> Biosample-specific z-scores are not in this call; the values above are maxima over biosamples.

<a id="e04"></a>**E04** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> ENCODE TF ChIP-seq at chr16:52565398:G>A: 215 peaks contain the variant, from 162 factors in 7 biosamples. In the matching biosample MCF-7: 16 peaks from 11 factors. No cCRE contains the variant. Bound factors outside the TF model collection (co-factors, Pol II, and TFs with no binding model; signs of an active element, not TF candidates): ARID4A, ARID5B, ASH2L, BCL3, CBX5, CHD4, CTBP1, EP300, GATAD1, GZF1, HBP1, HDAC1 (+51 more). Bound, expressed TFs with a binding model: 79; listed one per row: FOXA1, GATA3, SPDEF, NR2F2, CEBPB, TCF7L2, MYBL2, SP1, YY1, MAX; also bound: JUND, GATAD2A, BHLHE40, ZGPAT, RXRA, ZNF609, RXRB, ZNF770, FOXP4, AHDC1, GMEB1, ZNF772, ZNF788P, HMG20B, ELF1, ELF3, RELA, TBX2, ERF, HMG20A, CREB1, MBD1, ATF1, CREM, FOSL2, THAP11, SOX13, MEF2A, ZNF703, FOXJ3 (+39 more). Bound but below 1 TPM: DLX6, ETS1, FOXA2, FOXA3, GFI1, HLF, HNF1A, HNF1B, HNF4A, MAFF. Assayed with no peak here: 49 TFs in the matching biosample, 425 only elsewhere; never assayed: 536.

<a id="e05"></a>**E05** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> FOXA1: bound here. 5 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7; also in A549, HepG2, liver (e.g. ENCSR126YEB). 88.38 TPM in DepMap:ACH-000019 (MCF7), rank 28 of 1626 TFs.

<a id="e06"></a>**E06** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> GATA3: bound here. 4 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000EWV). 346.04 TPM in DepMap:ACH-000019 (MCF7), rank 5 of 1626 TFs.

<a id="e07"></a>**E07** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> SPDEF: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR042GSX). 72.51 TPM in DepMap:ACH-000019 (MCF7), rank 40 of 1626 TFs.

<a id="e08"></a>**E08** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> NR2F2: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000BUY). 38.14 TPM in DepMap:ACH-000019 (MCF7), rank 103 of 1626 TFs.

<a id="e09"></a>**E09** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> CEBPB: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000BSR). 24.33 TPM in DepMap:ACH-000019 (MCF7), rank 169 of 1626 TFs.

<a id="e10"></a>**E10** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> TCF7L2: bound here. 1 ENCODE ChIP-seq peak(s) contain the variant, in the matching biosample MCF-7 (e.g. ENCSR000EWT). 4.89 TPM in DepMap:ACH-000019 (MCF7), rank 642 of 1626 TFs.

<a id="e11"></a>**E11** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> MYBL2: bound elsewhere. 4 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: HepG2 (e.g. ENCSR581KCO). 49.2 TPM in DepMap:ACH-000019 (MCF7), rank 66 of 1626 TFs.

<a id="e12"></a>**E12** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> SP1: bound elsewhere. 4 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: A549, liver (e.g. ENCSR000BPE). 33.01 TPM in DepMap:ACH-000019 (MCF7), rank 122 of 1626 TFs.

<a id="e13"></a>**E13** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> YY1: bound elsewhere. 3 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: liver (e.g. ENCSR382MOM). 61.08 TPM in DepMap:ACH-000019 (MCF7), rank 48 of 1626 TFs.

<a id="e14"></a>**E14** occupancy, ENCODE TF ChIP-seq (Factorbook peaks; ENCODE experiment search) (https://factorbook.api.wenglab.org/graphql; retrieved local)

> MAX: bound elsewhere. 2 ENCODE ChIP-seq peak(s) contain the variant, only in other biosamples: liver (e.g. ENCSR521IID). 76.95 TPM in DepMap:ACH-000019 (MCF7), rank 35 of 1626 TFs.

<a id="e15"></a>**E15** gwas_lookup, GWAS Catalog REST v2 (https://www.ebi.ac.uk/gwas/rest/api/v2/associations?rs_id=rs56007086&size=100; retrieved 2026-10-26T02:25:35+00:00)

> 0 GWAS Catalog associations for rs56007086, strongest first:

<a id="e16"></a>**E16** finemap_lookup, Open Targets Platform (https://api.platform.opentargets.org/api/v4/graphql; retrieved 2026-10-26T02:25:34+00:00)

> Open Targets has no record of 16_52565398_G_A.

<a id="e17"></a>**E17** eqtl_lookup, GTEx Portal API v2 (gtex_v8) (https://gtexportal.org/api/v2/association/singleTissueEqtl?variantId=chr16_52565398_G_A_b38&datasetId=gtex_v8; retrieved 2026-10-26T02:27:56+00:00)

> 0 significant GTEx v8 single-tissue eQTLs for chr16_52565398_G_A_b38. NES is the effect of the alt allele (A) relative to ref (G).

<a id="e18"></a>**E18** literature_search, Europe PMC REST (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=TOX3%20AND%20%22breast%20cancer%22&format=json&pageSize=8&resultType=core; retrieved 2026-10-26T02:25:47+00:00)

> Europe PMC: 586 hits for 'TOX3 AND "breast cancer"'; top 7 with PMIDs:
> PMID 41230718 (2026): Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation.
> PMID 41849381 (2026): A transcription regulator atlas identifies TOX3 as an Atoh1 coactivator in cerebellar development and tumorigenesis.
> PMID 41595182 (2026): Identification and Characterisation of Canine Osteosarcoma Biomarkers and Therapeutic Targets.
> PMID 41596432 (2026): Bone Metastasis in Estrogen Receptor-Positive Breast Cancer: Molecular Insights and Therapeutic Advances.
> PMID 40932605 (2025): Molecular signatures of breast cancer in the Iranian population: a review of cell growth and cell cycle regulators.
> PMID 42700350 (2026): Interactions between circular RNAs (circRNAs) and the Hippo pathway in cancer.
> PMID 41871294 (2026): A reanalysis of a genome-wide association study on breast cancer in Asian populations using the SG10K_Health reference panel for imputation: a multi-Centre case-control analysis.

<a id="e18a"></a>**E18a** literature_search, Europe PMC abstract, PMID 41230718 (https://europepmc.org/article/MED/41230718; retrieved 2026-10-26T02:25:47+00:00)

> Key examples include promoter mutations [e.g., rs2279744 (Mouse double minute 2 homolog gene; MDM2)], enhancer mutations [e.g., rs4784227 (thymocyte selection-associated high mobility group box family member 3 gene; TOX3)], and lncRNAs [e.g., HOX transcript antisense intergenic RNA (HOTAIR)] linked to progression, metastasis, and poor survival.

<a id="e18b"></a>**E18b** literature_search, Europe PMC abstract, PMID 41871294 (https://europepmc.org/article/MED/41871294; retrieved 2026-10-26T02:25:47+00:00)

> Differences in panel performance influenced association signals, including breast cancer candidate loci such as FGFR2, TOX3, and ESR1.

<a id="e19"></a>**E19** literature_search, Europe PMC REST (https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=rs56007086%20allele-specific%20FOXA1%20GATA3%20SPDEF%20NR2F2%20binding%20breast%20cancer&format=json&pageSize=8&resultType=core; retrieved 2026-10-26T02:34:32+00:00)

> Europe PMC: 0 hits for 'rs56007086 allele-specific FOXA1 GATA3 SPDEF NR2F2 binding breast cancer'; top 0 with PMIDs:

<a id="e20"></a>**E20** eqtl_lookup, GTEx Portal API v2 (gtex_v8) (https://gtexportal.org/api/v2/association/singleTissueEqtl?variantId=chr16_52565398_G_A_b38&datasetId=gtex_v8; retrieved 2026-10-26T02:27:56+00:00)

> 0 significant GTEx v8 single-tissue eQTLs for chr16_52565398_G_A_b38 in tissues matching 'Breast - Mammary Tissue'. NES is the effect of the alt allele (A) relative to ref (G).

<a id="e21"></a>**E21** gene_disease, Open Targets Platform (https://api.platform.opentargets.org/api/v4/graphql; retrieved 2026-10-26T02:34:32+00:00)

> Open Targets: TOX3 and breast cancer (MONDO_0007254), overall score 0.58; by evidence type: genetic_association 0.91, literature 0.89
